Avanos Medical

AVNS

Market cap $545M

Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.

Avanos Medical, Inc. ( AVNS ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Jason Pickett - Vice President of Tax & Treasurer David Pacitti - CEO & Director Scott Galovan - CFO & Senior VP Conference Call Participants Daniel Stauder - Citizens JMP Securities, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Avanos Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Wednesday, November 5, 2025.

Avanos Medical (AVNS) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.36 per share a year ago.

Delivered double-digit growth in Specialty Nutrition Systems segment Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment Raising and narrowing top-line guidance and adjusted EPS guidance for the full year ALPHARETTA, Ga. , Nov. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial results.

ALPHARETTA, Ga. , Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed.

ANN ARBOR, Mich. , Oct. 23, 2025 /PRNewswire/ -- WRS Group, LLC (WRS), a privately held company based in Ann Arbor, Michigan, announced today that it has entered into a definitive agreement with Avanos Medical, Inc. (NYSE: AVNS) to acquire substantially all assets and rights related to Avanos' US Game Ready® orthopedic rental business.

Avanos Medical is deeply undervalued, with strong international expansion, aggressive M&A strategy, and a new CFO poised to drive inorganic growth. AVNS operates in high-growth markets, maintains a solid balance sheet with low debt, and trades at a significant discount to sector peers on earnings and book value. Ongoing transformation, divestitures, and stock repurchases are expected to enhance operating and free cash flow margins, further boosting investor appeal.

AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.

ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.

AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.